List of Excipients in Branded Drug DIPROLENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0575	PETROLATUM
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0575	PROPYLENE GLYCOL
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0575	PROPYLENE GLYCOL MONOPALMITOSTEARATE
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0575	WHITE WAX
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0962	HYDROXYPROPYL CELLULOSE
Merck Sharp & Dohme Corp	DIPROLENE	betamethasone dipropionate	0085-0962	ISOPROPYL ALCOHOL

DIPROLENE Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

DIPROLENE is a prescription topical corticosteroid containing augmented betamethasone dipropionate 0.05%. Its commercial differentiation depends less on active-ingredient exclusivity and more on vehicle performance, tolerability, sensory profile, manufacturing efficiency, and regulatory execution. The strongest opportunities are preservative-reduced creams, low-sting gels, high-occlusion ointments, and differentiated topical delivery systems that can support a generic, authorized-generic, or 505(b)(2) strategy.

What products and dosage forms does DIPROLENE contain?

DIPROLENE has been marketed in topical ointment, gel, and cream presentations. The products are indicated for corticosteroid-responsive dermatoses and are generally used twice daily for limited treatment periods. FDA labeling restricts use by age, treatment duration, body site, and weekly quantity because of the potency of the corticosteroid.[1]

Product	Strength	Primary vehicle profile	Commercial role
DIPROLENE ointment	0.05%	Anhydrous mineral oil and petrolatum base	Maximum occlusion and barrier support
DIPROLENE gel	0.05%	Carbomer-based aqueous gel with propylene glycol	Faster-spreading, less greasy presentation
DIPROLENE AF cream	0.05%	Preserved oil-in-water emulsion	More cosmetically acceptable daily-use vehicle

The “augmented” designation relates to the betamethasone dipropionate active ingredient used in the product and should not be confused with a separate active pharmaceutical ingredient. Regulatory submissions must establish the identity, strength, quality, and performance of the specific active ingredient and dosage form.

What excipients are used in DIPROLENE?

The principal excipient strategy differs by dosage form.

DIPROLENE ointment excipients

The ointment uses mineral oil and white petrolatum.[1] This is a simple anhydrous system with several commercial advantages:

• Low microbial risk because the formulation contains no water.
• Strong occlusive performance.
• Relatively simple manufacturing.
• Low preservative burden.
• Good compatibility with a potent lipophilic corticosteroid.

The main disadvantages are greasiness, poor cosmetic acceptability, transfer to clothing, and limited patient preference for use on visible or hairy areas.

An ointment competitor can differentiate through petrolatum grade, mineral-oil viscosity, particle-size control, spreadability, tack, residue, and packaging. A preservative-free anhydrous formulation does not by itself create a meaningful patent barrier, but it can support a product-positioning advantage.

DIPROLENE gel excipients

The gel uses carbomer 934P, propylene glycol, purified water, and sodium hydroxide.[1] Carbomer provides viscosity and suspension or dispersion control. Sodium hydroxide neutralizes the polymer and establishes the final rheology and pH.

The gel has a different user proposition from the ointment:

• Less greasy after application.
• Better suitability for hairy or intertriginous areas.
• Potentially faster drying.
• Greater sensitivity to pH, polymer grade, neutralization, and mixing conditions.
• Higher microbial-control requirements because the vehicle contains water.

The principal formulation risks are phase separation, viscosity drift, drug crystallization, pH instability, and excessive stinging. A developer can improve the platform through carbomer selection, alternative neutralizers, humectant optimization, and lower-irritancy solvent systems.

DIPROLENE AF cream excipients

The cream label identifies cetostearyl alcohol, chlorocresol, mineral oil, phosphoric acid, purified water, sodium phosphate monobasic monohydrate, and stearyl alcohol as inactive ingredients.[2]

This composition provides:

• An oil-in-water emulsion suitable for broader cosmetic use.
• Fatty alcohols for structure and emulsion stabilization.
• Mineral oil for emolliency.
• Chlorocresol as preservative.
• Phosphate components for pH control.
• Greater patient acceptability than an ointment for many body sites.

Chlorocresol is a potential differentiation point. A preservative-free or alternative-preservative cream could address sensitivity concerns, although it would require preservative efficacy testing, container-closure assessment, microbial limits testing, and a complete stability package.

Which excipient opportunities have the highest commercial value?

The most attractive opportunities are products that improve tolerability or usability without changing the therapeutic claim.

Opportunity	Excipient or vehicle direction	Commercial rationale	Regulatory complexity
Low-sting gel	Reduce propylene glycol or replace part of the solvent system	Addresses burning and irritation	Moderate
Preservative-free cream	Sterile or low-bioburden manufacturing, airless packaging, or alternative preservation system	Targets sensitive-skin users	High
Non-greasy emulsion	Lower mineral-oil load, optimized fatty-alcohol system	Improves adherence and cosmetic acceptability	Moderate
High-occlusion ointment	Petrolatum and mineral-oil rheology optimization	Supports severe xerosis and barrier impairment	Low to moderate
Hair-bearing-site gel	Fast-spreading carbomer or cellulose-based gel	Improves application to scalp and intertriginous areas	Moderate
Foam or spray	Hydroalcoholic, emulsion, or propellant-based delivery	Enables scalp and large-area application	High
Bioadhesive hydrogel	Polymer system that increases residence time	May support less frequent application	High
Barrier-support cream	Addition of nonactive emollient or barrier excipients	Supports eczema-oriented positioning	Moderate to high

The strongest near-term opportunity is a differentiated cream or gel. Foam, spray, and bioadhesive platforms have higher development costs and greater regulatory risk, but they offer more meaningful product differentiation than a conventional generic ointment.

What excipient strategy best fits a generic DIPROLENE product?

A conventional generic should prioritize formulation similarity, manufacturing robustness, and a clean topical equivalence package.

Ointment strategy

An ointment generic should use a simple anhydrous base with:

• Controlled petrolatum-to-mineral-oil ratio.
• Consistent drug dispersion.
• Tight control of milling and homogenization.
• Low risk of grittiness or drug crystallization.
• A tube or pump package that limits contamination and improves dose consistency.

The commercial advantage is cost efficiency. The limitation is weak differentiation because many competitors can reproduce the same vehicle profile.

Gel strategy

A gel generic should optimize:

• Carbomer grade and concentration.
• Neutralization endpoint.
• pH and viscosity.
• Drug particle size and suspension stability.
• Propylene glycol concentration.
• Drying time and residue.
• Skin irritation and sting.

Carbomer substitution can create meaningful performance differences. It can also complicate equivalence because changes in polymer grade affect rheology, drug release, spreadability, and skin deposition.

Cream strategy

A cream generic should focus on:

• Droplet-size distribution.
• Emulsion type and physical stability.
• Preservative concentration.
• Fatty-alcohol ratio.
• pH buffering.
• Drug solubilization versus suspension.
• In-vitro release and skin permeation behavior.

A cream with lower preservative exposure and improved sensory properties may support a premium generic or co-branded product, but the product must remain within the regulatory boundaries for the reference dosage form.

How can excipients support FDA approval?

For a conventional ANDA, the formulation must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA framework. Topical products often require a combination of comparative physicochemical characterization, in-vitro release testing, and, where applicable, in-vitro permeation or clinical endpoint data.[3]

Critical quality attributes include:

• Appearance and homogeneity.
• Assay and content uniformity.
• Particle-size distribution.
• Viscosity and rheology.
• pH.
• Globule or droplet size for emulsions.
• Water activity and microbial quality.
• Preservative content and effectiveness.
• In-vitro release rate.
• Stability under labeled storage conditions.

FDA’s topical-product guidance places increasing emphasis on product microstructure and performance rather than simple ingredient matching.[3] A formulation with a different excipient grade may be acceptable, but the sponsor must show that the difference does not alter product performance.

A 505(b)(2) pathway may be more appropriate for a new dosage form, such as a foam, spray, or bioadhesive formulation, when the product cannot be supported as a conventional generic. That pathway offers more formulation flexibility but usually requires additional clinical or bridging evidence.

What patents protect DIPROLENE and when does it lose exclusivity?

The original commercial exclusivity and composition protection for DIPROLENE are long expired. Augmented betamethasone dipropionate is an established topical corticosteroid, and multiple generic products have historically entered the U.S. market.

For commercial planning, the key distinction is between:

1. Active-ingredient patent protection.
2. Vehicle or formulation patents.
3. Method-of-use patents.
4. Manufacturing-process patents.
5. Trademark and trade-dress protection.
6. Regulatory exclusivity.

The historical DIPROLENE estate does not appear to provide a durable, broad patent barrier against conventional generic ointment, cream, or gel development. Any current Orange Book-listed patent must be evaluated against the specific reference-listed drug and NDA record because patent listings can differ by dosage form and product presentation.[4]

Orange Book status

The relevant FDA review should cover:

• The reference-listed DIPROLENE NDA.
• DIPROLENE AF cream, if listed separately.
• Product-specific patent listings.
• Pediatric exclusivity.
• Current marketing status.
• Approved generic equivalents.

No commercial strategy should assume that a legacy brand trademark or historical formulation patent blocks ANDA entry. The practical protection for the brand is more likely to come from physician familiarity, distribution, formulary position, and patient recognition.

Are there Paragraph IV challenges or DIPROLENE patent settlements?

DIPROLENE is a mature topical product with generic competition. The principal Paragraph IV risk is therefore associated with any later-added formulation, delivery-system, or method-of-use patent rather than the original corticosteroid product.

A Paragraph IV applicant could challenge:

• A listed formulation patent.
• A gel or emulsion composition claim.
• A specific particle-size or crystallinity limitation.
• A vehicle-dependent release profile.
• A method-of-use claim covering a defined dermatologic condition.

For a mature product, an early Paragraph IV challenge is less likely to produce a large first-filer prize than it would for a high-revenue oral drug. The value proposition may instead come from manufacturing scale, state substitution, contract sales, or a differentiated vehicle.

No widely recognized, commercially material settlement framework defines the current DIPROLENE market. Any applicant should review current FDA Orange Book listings, ANDA litigation records, and district-court dockets before relying on a freedom-to-operate conclusion.[4,5]

What manufacturing and intellectual-property barriers matter?

The active ingredient is commercially available, so manufacturing barriers are concentrated in formulation and quality control.

Ointment barriers

The main risks are:

• Incomplete drug dispersion.
• Particle agglomeration.
• Overheating during compounding.
• Batch-to-batch variation in yield stress.
• Poor dose uniformity from tube filling.

Gel barriers

The main risks are:

• Carbomer hydration variability.
• Inconsistent neutralization.
• Drug precipitation.
• Viscosity loss during storage.
• Microbial contamination.

Cream barriers

The main risks are:

• Emulsion inversion.
• Droplet-size growth.
• Preservative partitioning.
• Drug migration between phases.
• Stability changes after freeze-thaw exposure.

Formulation patents may protect the interaction between the active ingredient and vehicle rather than any single excipient. A patent strategy is stronger when it claims measurable performance, such as a defined release profile, particle-size range, rheological window, or stability result. Broad claims covering petrolatum, mineral oil, carbomer, or fatty alcohols alone are more vulnerable to prior-art challenges.

Which companies are competing in the augmented betamethasone dipropionate market?

Competition includes the brand owner, generic dermatology companies, and manufacturers with established topical manufacturing platforms. Relevant competitive categories include:

• Authorized or branded generic products.
• ANDA products for ointment, cream, and gel.
• Contract manufacturers producing dermatology semisolids.
• Companies with topical foam, spray, and emulsion technology.
• Specialty dermatology companies using physician-directed distribution.

The most important competitive variables are product availability, wholesale acquisition cost, payer substitution, tube size, pharmacy inventory, and dosage-form preference. A low-cost ointment can compete on access, while a cream or gel can command a higher commercial value if it improves use on the scalp, face-adjacent areas, or large surface areas without compromising the corticosteroid label.

What revenue exposure and launch scenarios are realistic?

DIPROLENE should be treated as a mature, competitive dermatology asset rather than a protected specialty pharmaceutical. Revenue exposure depends on product form:

Launch scenario	Expected positioning	Primary risk
Standard ointment generic	Lowest-cost substitution	Price erosion
Standard cream generic	Broad pharmacy access	Limited differentiation
Improved gel	Premium generic or specialty dermatology	Equivalence and tolerability evidence
Preservative-reduced cream	Sensitive-skin positioning	Stability and preservation requirements
Foam or spray	Scalp and large-area use	Higher development and regulatory cost
Authorized generic	Brand-linked distribution	Lower gross margin and channel dependence

The most defensible commercial strategy is a two-tier portfolio: a low-cost conventional ointment or cream for formulary access, paired with a differentiated gel or emulsion for higher-margin dermatology channels.

How does DIPROLENE compare with other topical corticosteroid opportunities?

DIPROLENE has a stronger potency profile than low- and mid-potency topical steroids, which increases the importance of vehicle selection and labeling controls. Compared with hydrocortisone, desonide, or triamcinolone products, augmented betamethasone dipropionate can support more limited, high-value treatment use but carries greater concern regarding skin atrophy, systemic absorption, and inappropriate long-term use.

Compared with clobetasol products, DIPROLENE may occupy a middle commercial position: potent enough for significant inflammatory dermatoses, but potentially more suitable for selected short-duration uses than the highest-potency corticosteroids. This positioning favors dosage-form differentiation rather than broad consumer marketing.

Key Takeaways

• DIPROLENE contains augmented betamethasone dipropionate 0.05% in ointment, gel, and cream presentations.
• The ointment relies on mineral oil and white petrolatum for occlusion and manufacturing simplicity.
• The gel uses carbomer, propylene glycol, water, and sodium hydroxide, creating opportunities for lower-sting and improved rheology.
• The cream uses an emulsion system with fatty alcohols, mineral oil, phosphate buffering, and chlorocresol preservation.
• Original DIPROLENE exclusivity is expired, and conventional generic entry is commercially established.
• The most attractive opportunities are differentiated creams and gels, not undifferentiated ointments.
• Preservative reduction, improved sensory properties, scalp application, and lower residue are commercially relevant excipient strategies.
• Foam, spray, and bioadhesive formulations offer stronger differentiation but require more complex regulatory support.
• Current Orange Book listings and litigation records must control any final patent or Paragraph IV assessment.
• A dual strategy combining a low-cost generic with a premium vehicle is more commercially viable than a single formulation approach.

FAQs

Can DIPROLENE be reformulated without changing the active ingredient?

Yes. A reformulation can change excipient grades, vehicle structure, preservative system, or delivery format, but the regulatory pathway depends on whether the product remains pharmaceutically equivalent to the reference product.

Is a preservative-free DIPROLENE cream commercially attractive?

Yes. A preservative-free or preservative-reduced cream could target patients with sensitivity concerns, but the formulation would require strong microbial-control, packaging, stability, and preservative-effectiveness support.

Which DIPROLENE dosage form is easiest to manufacture?

The ointment is generally the simplest because it is anhydrous and has a limited excipient system. The gel and cream require tighter control of hydration, pH, rheology, microbial quality, and physical stability.

Can a new DIPROLENE foam obtain meaningful patent protection?

Potentially. Patent strength would depend on technical limitations such as foam stability, drug particle size, delivery performance, skin deposition, container system, or manufacturing process. A generic foam would not automatically be blocked by legacy patents covering the original ointment or cream.

Is DIPROLENE suitable for a 505(b)(2) product?

A 505(b)(2) strategy may be suitable for a materially different dosage form, such as a foam, spray, or bioadhesive system, where conventional ANDA requirements cannot adequately address the formulation or delivery differences.

References

1. U.S. Food and Drug Administration. (2023). DIPROLENE: Augmented betamethasone dipropionate ointment and gel prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2023). DIPROLENE AF: Augmented betamethasone dipropionate cream prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Generic drug user fee amendments: ANDA and patent certification resources. U.S. Department of Health and Human Services.